Syncope and Cerebral Venous Thrombosis: Evaluation and Management
Syncope is an uncommon but recognized presenting symptom of cerebral venous thrombosis (CVT), and when CVT is suspected in a patient with syncope, immediate venographic imaging (CTV or MRV) is mandatory even if initial CT/MRI is normal, followed by urgent anticoagulation with low molecular weight heparin and admission to a stroke unit.
Clinical Recognition and Diagnostic Approach
When to Suspect CVT in Syncope Patients
CVT should be considered in syncope presentations with:
- Headache preceding or accompanying the syncopal event 1
- Young patients (particularly women of reproductive age) 2
- Prothrombotic risk factors (oral contraceptives, pregnancy/puerperium, recent infection, inflammatory conditions) 3
- Focal neurological deficits developing after syncope 1
- Seizures associated with the event 2
Critical pitfall: Syncope from CVT can occur with isolated mental status changes or confusion, particularly in elderly patients with deep venous system involvement 3. The 2017 ACC/AHA syncope guidelines do not specifically address CVT as a cause, but the atypical presentation warrants neurological evaluation 4.
Imaging Algorithm
- Initial imaging: Non-contrast CT is often normal (only 30% show abnormalities in CVT) 3
- Mandatory venographic study: CTV or MRV must be performed when CVT is suspected, regardless of normal initial CT/MRI 3
- Do NOT rely on D-dimer: D-dimer testing cannot rule out CVT and should not be routinely performed 5
The absence of findings on plain CT or MRI does not exclude CVT 3. Venographic imaging is Class I, Level C recommendation 3.
Acute Management Protocol
Immediate Actions
Anticoagulation should be initiated immediately upon diagnosis, even in the presence of intracranial hemorrhage 3, 2. The evidence strongly supports this approach:
- Preferred agent: Low molecular weight heparin (LMWH) over unfractionated heparin 5
- Dosing: Nadroparin 180 anti-factor Xa units/kg daily in 2 divided doses, or equivalent LMWH 3
- Alternative: Unfractionated heparin with aPTT target 2× baseline if LMWH contraindicated 3
The landmark trials showed dramatic mortality reduction with anticoagulation: In the heparin trial, 3/10 patients died in the placebo group versus 0/10 in the heparin group, with complete recovery in 8/10 heparin patients 3.
Setting of Care
Admit to a stroke unit for organized interdisciplinary care 3. Stroke unit care reduces:
- Death at 1 year (OR 0.86)
- Death or institutionalization (OR 0.82)
- Death or dependency (OR 0.82) 3
Monitoring and Follow-up Imaging
- Early repeat CTV/MRV: For patients with persistent/evolving symptoms or suspected thrombus propagation 3
- Follow-up imaging at 3-6 months: To assess recanalization in stable patients 3
Management of Complications
Neurological Deterioration Despite Anticoagulation
If the patient worsens on adequate anticoagulation:
- Consider endovascular recanalization at a neurointerventional center on an individual basis 5
- Surgical decompression: Should be performed for patients with parenchymal lesions (hemorrhage/edema) and impending herniation to prevent death 5
Seizure Management
Seizures are common in CVT presentations 2. Standard antiepileptic therapy should be initiated if seizures occur.
Long-term Anticoagulation
After the acute phase:
- Direct oral anticoagulants (DOACs) preferred over warfarin for 3-12 months 5, 6
- Duration: 3-6 months minimum to prevent recurrence and enhance recanalization 6
- Thrombophilia screening: Consider only in young patients, spontaneous CVT, recurrent thrombosis, or positive family history—not routinely recommended 5
Driving Restrictions
Per the 2017 ACC/AHA syncope guidelines, patients with syncope of undetermined etiology should refrain from driving for 1 month 4. However, given CVT is a determined cause with specific treatment, driving restrictions should follow stroke guidelines and be individualized based on neurological recovery and seizure risk.
Special Populations
Women of reproductive age: